Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 5/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715068 | 1.00 | ENPP3 (0.49) | ENPP3ENPP1ENPP2THRBALDH1A1 | |
| SCHEMBL4715066 | 1.00 | ENPP3 (0.49) | ENPP3ENPP1ENPP2THRBALDH1A1 | |
| SCHEMBL4716205 | 0.87 | MAPT (0.46) | ENPP2ALDH1A1MAPTTP53MEN1 | |
| SCHEMBL4716212 | 0.87 | MAPT (0.46) | ENPP2ALDH1A1MAPTTP53MEN1 | |
| SCHEMBL4716209 | 0.87 | MAPT (0.46) | ENPP2ALDH1A1MAPTTP53MEN1 | |
| SCHEMBL4716255 | 0.84 | NPY2R (0.47) | ALDH1A1MAPTLMNAGAAMEN1 | |
| SCHEMBL4720462 | 0.82 | ENPP3 (0.47) | ENPP3ENPP1ENPP2ALDH1A1MAPT | |
| SCHEMBL4720465 | 0.82 | ENPP3 (0.47) | ENPP3ENPP1ENPP2ALDH1A1MAPT | |
| SCHEMBL5480697 | 0.82 | SLC6A2 (0.59) | ALDH1A1LMNA | |
| SCHEMBL4716139 | 0.82 | SLC6A2 (0.59) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | ENPP3 1263/4885ENPP1 1794/4885ENPP2 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.